Carfilzomib versus bortezomib: no longer an ENDEAVOR

Research output: Contribution to journal › Comment/Letter to the editor › Academic

11 Citations (Scopus)

Access to Document

@article{f0a07a4017c747b8a31c52514ff3a071,

title = "Carfilzomib versus bortezomib: no longer an ENDEAVOR",

author = "{van de Donk}, {Niels WCJ}",

year = "2017",

month = oct,

day = "1",

doi = "https://doi.org/10.1016/S1470-2045(17)30613-7",

language = "English",

volume = "18",

pages = "1288--1290",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "10",

}

TY - JOUR

T1 - Carfilzomib versus bortezomib

T2 - no longer an ENDEAVOR

AU - van de Donk, Niels WCJ

PY - 2017/10/1

Y1 - 2017/10/1

UR - http://www.scopus.com/inward/record.url?scp=85028086304&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/S1470-2045(17)30613-7

DO - https://doi.org/10.1016/S1470-2045(17)30613-7

M3 - Comment/Letter to the editor

SN - 1470-2045

VL - 18

SP - 1288

EP - 1290

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 10

ER -